Given the increasingly clear patient outcome benefits of accurately localizing prostate cancer lesions at the earliest stage of recurrence, our observations suggest a potential value of 68Ga-PSMA-11 PET/CT in the very low PSA BCR setting, especially in cases with more rapid PSA doubling time or with high-risk histology. The gene discussed is BCR; the disease is prostate cancer.